- Home
- CANF vs SGLY Comparison
CANF vs SGLY Comparison
Compare CANF & SGLY Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CANF
- SGLY
- Stock Information
- Founded
- CANF 1994
- SGLY 2001
- Country
- CANF Israel
- SGLY United States
- Employees
- CANF N/A
- SGLY N/A
- Industry
- CANF Biotechnology: Pharmaceutical Preparations
- SGLY
- Sector
- CANF Health Care
- SGLY
- Exchange
- CANF Nasdaq
- SGLY Nasdaq
- Market Cap
- CANF 13.5M
- SGLY 3.9M
- IPO Year
- CANF N/A
- SGLY 2008
- Fundamental
- Price
- CANF $1.04
- SGLY $0.97
- Analyst Decision
- CANF Strong Buy
- SGLY
- Analyst Count
- CANF 2
- SGLY 0
- Target Price
- CANF $14.00
- SGLY N/A
- AVG Volume (30 Days)
- CANF 145.3K
- SGLY 54.0K
- Earning Date
- CANF 08-29-2025
- SGLY 08-26-2025
- Dividend Yield
- CANF N/A
- SGLY N/A
- EPS Growth
- CANF N/A
- SGLY N/A
- EPS
- CANF N/A
- SGLY N/A
- Revenue
- CANF $674,000.00
- SGLY $2,172,036.00
- Revenue This Year
- CANF $461.72
- SGLY N/A
- Revenue Next Year
- CANF N/A
- SGLY N/A
- P/E Ratio
- CANF N/A
- SGLY N/A
- Revenue Growth
- CANF N/A
- SGLY N/A
- 52 Week Low
- CANF $0.98
- SGLY $0.54
- 52 Week High
- CANF $4.69
- SGLY $7.65
- Technical
- Relative Strength Index (RSI)
- CANF 44.37
- SGLY 44.84
- Support Level
- CANF $1.00
- SGLY $0.93
- Resistance Level
- CANF $1.09
- SGLY $1.15
- Average True Range (ATR)
- CANF 0.03
- SGLY 0.08
- MACD
- CANF 0.00
- SGLY -0.01
- Stochastic Oscillator
- CANF 49.50
- SGLY 4.35
About CANF Can-Fite Biopharma Ltd Sponsored ADR (Israel)
Can Fite Biofarma Ltd is an clinical-stage biopharmaceutical company. The company develops orally bioavailable small molecule therapeutic products for the treatment of cancer, liver and inflammatory diseases and erectile dysfunction. The company's platform technology utilizes the Gi protein associated A3 adenosine receptor, or A3AR, as a therapeutic target. The company's drug candidate, Piclidenoson, is currently in a Phase III trial for psoriasis. Can-Fite's liver drug, Namodenoson, is headed into a Phase III trial for hepatocellular carcinoma (HCC), the common form of liver cancer, and a Phase IIb trial for the treatment of non-alcoholic steatohepatitis (NASH).
About SGLY Singularity Future Technology Ltd.
Singularity Future Technology Ltd is an investment holding company. The company's operating segment includes Freight Logistics Services and Sale of Crypto-mining Machines. It generates maximum revenue from the Freight Logistics Services segment. Geographically, it derives a majority of its revenue from China.